Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVpreF vaccine in children 2 to <18 years (PICASSO)
NCT05900154Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV) (6 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Local Reactions, Percentage of Participants With Systemic Events and 3 more. Started Jun 2023; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05900154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900154.